FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019821829> ?p ?o ?g. }

• W2019821829 endingPage "1050" @default.
• W2019821829 startingPage "1046" @default.
• W2019821829 abstract "Inhibin is a polypeptide hormone produced by the granulosa cells of the ovary, and is present in body fluids as dimers of various sizes each comprising an alpha- and beta-subunit. Free forms of the alpha-subunit also circulate, and the presently available radioimmunoassay (Monash assay) cannot distinguish these from biologically active dimeric inhibin. Recently we described a new two-site enzyme immunoassay able for the first time to measure the levels of dimeric inhibin throughout the human menstrual cycle. The sensitivity limit of this assay is 2 pg ml-1 in human serum with cross-reactivity against activin of 0.05%. The normal range of inhibin in post-menopausal women is < 5 pg ml-1, in pre-menopausal women 2-80 pg ml-1 (2-10 pg ml-1 in the follicular phase, 40-80 pg ml-1 in the luteal phase). This assay was used to determine inhibin levels in sera from 15 (five pre-menopausal and ten post-menopausal) patients with granulosa cell tumours of the ovary. It was raised in a pre-menopausal patient preoperatively (261 pg ml-1), in six post-menopausal patients (32, 43, 54, 66, 24 and 58 pg ml-1) and one pre-menopausal patient with recurrent tumour, (237 pg ml-1), all confirmed clinically. Inhibin was normal in six patients in remission. Oestradiol levels were normal in all patients. Serial levels of inhibin predicted recurrence before overt clinical relapse in two patients. In 29 patients with malignant epithelial ovarian tumours inhibin levels were modestly elevated in nine and normal in the rest. Three patients with endometrioid histology, two with undifferentiated tumours, three with mucinous adenocarcinoma and one with clear cell carcinoma had elevated inhibin levels. Functional inhibin is secreted by all granulosa cell tumours of the ovary studied and can be used as a tumour marker to determine response to therapy and predict recurrence and is superior to oestradiol. A more detailed analysis of the levels of inhibin, and its subunits in epithelial ovarian cancer is needed to identify the molecular forms of the immunoreactive material before optimised assays can be applied to this more common tumour." @default.
• W2019821829 created "2016-06-24" @default.
• W2019821829 creator A5021137595 @default.
• W2019821829 creator A5030557539 @default.
• W2019821829 creator A5066516973 @default.
• W2019821829 creator A5067306327 @default.
• W2019821829 creator A5075224523 @default.
• W2019821829 date "1995-05-01" @default.
• W2019821829 modified "2023-10-06" @default.
• W2019821829 title "Inhibin as a marker for ovarian cancer" @default.
• W2019821829 cites W1951029407 @default.
• W2019821829 cites W1966783413 @default.
• W2019821829 cites W2007497470 @default.
• W2019821829 cites W2022716177 @default.
• W2019821829 cites W2029131356 @default.
• W2019821829 cites W2033162087 @default.
• W2019821829 cites W2047043642 @default.
• W2019821829 cites W2055332599 @default.
• W2019821829 cites W2081626609 @default.
• W2019821829 cites W2086773297 @default.
• W2019821829 cites W2121970442 @default.
• W2019821829 cites W2155492518 @default.
• W2019821829 cites W2330282086 @default.
• W2019821829 cites W2396175520 @default.
• W2019821829 cites W2615946525 @default.
• W2019821829 doi "https://doi.org/10.1038/bjc.1995.201" @default.
• W2019821829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2033765" @default.
• W2019821829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7734297" @default.
• W2019821829 hasPublicationYear "1995" @default.
• W2019821829 type Work @default.
• W2019821829 sameAs 2019821829 @default.
• W2019821829 citedByCount "102" @default.
• W2019821829 countsByYear W20198218292012 @default.
• W2019821829 countsByYear W20198218292013 @default.
• W2019821829 countsByYear W20198218292015 @default.
• W2019821829 countsByYear W20198218292016 @default.
• W2019821829 countsByYear W20198218292018 @default.
• W2019821829 countsByYear W20198218292020 @default.
• W2019821829 countsByYear W20198218292021 @default.
• W2019821829 countsByYear W20198218292022 @default.
• W2019821829 countsByYear W20198218292023 @default.
• W2019821829 crossrefType "journal-article" @default.
• W2019821829 hasAuthorship W2019821829A5021137595 @default.
• W2019821829 hasAuthorship W2019821829A5030557539 @default.
• W2019821829 hasAuthorship W2019821829A5066516973 @default.
• W2019821829 hasAuthorship W2019821829A5067306327 @default.
• W2019821829 hasAuthorship W2019821829A5075224523 @default.
• W2019821829 hasBestOaLocation W20198218291 @default.
• W2019821829 hasConcept C121608353 @default.
• W2019821829 hasConcept C126322002 @default.
• W2019821829 hasConcept C134018914 @default.
• W2019821829 hasConcept C143228043 @default.
• W2019821829 hasConcept C159654299 @default.
• W2019821829 hasConcept C176685330 @default.
• W2019821829 hasConcept C187785154 @default.
• W2019821829 hasConcept C203014093 @default.
• W2019821829 hasConcept C2777164284 @default.
• W2019821829 hasConcept C2777203538 @default.
• W2019821829 hasConcept C2778324911 @default.
• W2019821829 hasConcept C2778562196 @default.
• W2019821829 hasConcept C2779058012 @default.
• W2019821829 hasConcept C2780420688 @default.
• W2019821829 hasConcept C2780427987 @default.
• W2019821829 hasConcept C71315377 @default.
• W2019821829 hasConcept C71924100 @default.
• W2019821829 hasConceptScore W2019821829C121608353 @default.
• W2019821829 hasConceptScore W2019821829C126322002 @default.
• W2019821829 hasConceptScore W2019821829C134018914 @default.
• W2019821829 hasConceptScore W2019821829C143228043 @default.
• W2019821829 hasConceptScore W2019821829C159654299 @default.
• W2019821829 hasConceptScore W2019821829C176685330 @default.
• W2019821829 hasConceptScore W2019821829C187785154 @default.
• W2019821829 hasConceptScore W2019821829C203014093 @default.
• W2019821829 hasConceptScore W2019821829C2777164284 @default.
• W2019821829 hasConceptScore W2019821829C2777203538 @default.
• W2019821829 hasConceptScore W2019821829C2778324911 @default.
• W2019821829 hasConceptScore W2019821829C2778562196 @default.
• W2019821829 hasConceptScore W2019821829C2779058012 @default.
• W2019821829 hasConceptScore W2019821829C2780420688 @default.
• W2019821829 hasConceptScore W2019821829C2780427987 @default.
• W2019821829 hasConceptScore W2019821829C71315377 @default.
• W2019821829 hasConceptScore W2019821829C71924100 @default.
• W2019821829 hasIssue "5" @default.
• W2019821829 hasLocation W20198218291 @default.
• W2019821829 hasLocation W20198218292 @default.
• W2019821829 hasLocation W20198218293 @default.
• W2019821829 hasLocation W20198218294 @default.
• W2019821829 hasOpenAccess W2019821829 @default.
• W2019821829 hasPrimaryLocation W20198218291 @default.
• W2019821829 hasRelatedWork W1566419909 @default.
• W2019821829 hasRelatedWork W2019821829 @default.
• W2019821829 hasRelatedWork W2023858769 @default.
• W2019821829 hasRelatedWork W2043899786 @default.
• W2019821829 hasRelatedWork W2082518763 @default.
• W2019821829 hasRelatedWork W2083415808 @default.
• W2019821829 hasRelatedWork W2090757166 @default.
• W2019821829 hasRelatedWork W2099602943 @default.
• W2019821829 hasRelatedWork W2112207893 @default.

• next